Grants / National Council on Disability / National Council on Disability

NCD-21-01: Notice of Funding Opportunity: State’s use of Quality-Adjusted Life Year (QALY) - Based Cost-Effectiveness Reports to Inform Medicaid Coverage for Prescription Drugs

Closed Closed July 20, 2021 Opportunity NCD-21-01 ☆ Save

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Council on Disability notices from 2021.

• Award ceiling$65,000
• Award floor$65,000
• Expected awards1
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• No cost sharing or match is required.

What the grant funds

The National Council on Disability (NCD) seeks proposals for a report that examines the extent of state’s use of QALY-based cost-effectiveness studies issued by the Institute for Clinical and Economic Review (ICER) or international drug prices set in reliance on QALY based cost-effectiveness research, to inform which prescription drugs and treatments will be covered by their Medicaid programs. The findings in the report serve to assist federal and state policymakers and Congress, with the insight needed to make policy decisions designed to ensure the continued availability of necessary prescription drugs to people with chronic illnesses and disabilities. The report will also provide patient rights organizations, medical associations and educators, and persons with disabilities, with an understanding of health care policies, legislation, and initiatives that impact their lives. The report will identify the states that are using ICER QALY-based cost studies or international drug prices to inform Medicaid coverage decisions; will describe how the studies are being used, e.g., as a benchmark or cost-threshold; and will identify if and how reliance on these reports has impacted coverage of drugs and treatments for beneficiaries. It will also describe methodological alternatives to QALYs that consider patient values and preferences. The report will include findings and make recommendations aimed at the U.S. Department of Health and Human Services, state governments, and Congress to address any identified issues and any barriers to accessing prescription drugs caused by reliance on these studies and/or international drug prices. The full Notice of Funding Opportunity is posted at www.ncd.gov under the "Funding Opportunities" tab and on the NCD Home Page.

Category: Other.

We found no grant awards under Assistance Listing 92.002 in fiscal 2021 to 2025, which usually means the program is new or very small.

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.